



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sheena M. Loosmore  
Appl'n. No. : 09/577,601  
Filed : May 25, 2000  
Title : CO-EXPRESSION OF RECOMBINANT PROTEINS  
Grp./A.U. : 1648  
Examiner : Zachariah Lucas  
Docket No. : 1038-1026 MIS/jb  
Date : December 2, 2002

#11.  
Omdt. B  
w/Ext (Comm.)  
12/12/02

RECEIVED  
DEC 06 2002

TECH CENTER 1600/2900

**BY COURIER**

The Commissioner of Patents  
and Trademarks,  
Box Amendment  
Washington, D.C. 20231,  
U.S.A.

12/03/2002 BABRAHA1 00000012 09577601

01 FC:1253

920.00 OP

-Ext. (3 mos.)

12/05/2002 BABRAHA1 00000012 09577601

02 FC:1806

180.00 OP

-IDS fees

**AMENDMENT**

Sir:

In response to the Office Action of June 4, 2002, please amend the  
above-identified application as follows:

**In the Specification:**

Please replace the paragraph beginning at page 3, line 9, with the following rewritten  
paragraph :

"A second family of high molecular weight adhesion proteins has been  
identified in about 25% of NTHI and in encapsulated *H. influenzae* strains (refs. 11,  
12, 13). The NTHi member of this second family is termed *Haemophilus influenzae*  
adhesin or Hia, and the homologous protein found in encapsulated strains is termed  
*Haemophilus influenzae* surface fibril protein or Hsf. The *hia* gene was originally  
cloned from an expression library using convalescent sera from an otitis media  
patient, which indicates that it is an important immunogen during disease.  
Production of the full-length recombinant Hia protein in *E. coli* appears to be toxic to  
the host, so a series of N-terminally truncated proteins was made as described in  
[copending] United States Patent No. 6,335,182 and in PCT Patent Application No.

Bid.  
cont'd.

11/15